Navigation Links
Oncology is the Most Active Therapeutic Area for Phase II/III R&D
Date:11/21/2013

BURLINGTON, Mass., Nov. 21, 2013 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that while metabolic drugs account for one-quarter of drugs recently filed for approval or approved, oncology continues to be the most active therapeutic area for Phase II and III research and development (R&D). Among the top 25 biopharmaceutical companies, oncology is the focus for 30 percent of Phase II drugs and 22 percent of Phase III drugs. According to Decision Resources' Strategic Insights report entitled R&D Trends: Will Pharma's Investment Deliver?, other active therapeutic areas of R&D include obesity drugs, anti-diabetics, anti-infectives, central nervous system drugs, musculoskeletal/pain drugs and respiratory drugs.

The analysis also reveals that despite enduring multiple failures in 2011 and 2012 with drugs in Phase III development, Novartis is poised to benefit from a rich Phase III pipeline. Decision Resources expects Novartis will replace Pfizer as the top global biopharmaceutical company in 2015.

"To maximize R&D investments, biopharmaceutical companies must continue to address Phase II and III attrition and identify better prospects early on," said Decision Resources Group Senior Vice President Kate Hohenberg. "As more than half of the costs associated with new drugs are accrued from Phase II on, this could lead to significant cost savings."

About Decision Resources
Decision Resources (www.decisionresources.com) is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources Group company.

About Decision Resources Group
Decision Resources Group is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources Group at www.DecisionResourcesGroup.com.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

For more information, contact:

Decision Resources Group
Christopher Comfort
781-993-2597
ccomfort@dresources.com


'/>"/>
SOURCE Decision Resources
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Genelux, a Leader in the Emerging Oncolytic Virotherapy Field, Receives Significant Industry Honor from Elsevier Business Intelligence, Identifying GL-ONC1 as One of 2013s Top Oncology Projects to Watch
2. QIAGEN Announces Partnership With Clovis Oncology to Co-develop Companion Diagnostic Targeting Drug-Resistant EGFR Mutations
3. In The Face Of Increasing Healthcare Spend And High-Cost Targeted Treatment, Market Access Barriers Continue To Rise For Targeted Oncology Drugs
4. Elekta Opens Global Education Center for Oncology and Neuroscience Professionals
5. Enhanced Strategies for Design and Execution of Biomarker-driven Oncology Trials, new life science webinar hosted by Xtalks
6. Cancer Patients to See More Precise Oncology Treatment via Innovative Life Sciences Coalition
7. Oncology Therapeutics Market in India to 2018 Report
8. Vermillions OVA1 Receives New Statement by Society of Gynecologic Oncology
9. Closed Drug Transfer Systems: Oncology Therapeutics Market Dynamics and Closed Drug Transfer Design Factors - Market Forecasts to 2017
10. Ambit Announces Presentation of Results from Phase 2 ACE Study of Quizartinib in Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML) at the Annual Meeting of the American Society of Clinical Oncology
11. AbbVie Presents Results from Phase I Study of Investigational Oncology Compound ABT-199 at American Society of Clinical Oncology Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/5/2016)... SAN DIEGO , Feb. 5, 2016 ... the region,s trusted information source for community, health and ... San Diego) will integrate to enhance care coordination ... people to the services they need and to better ... to improve care.   San Diego ...
(Date:2/4/2016)... ... February 04, 2016 , ... ... and compliance training, today announced an interactive FDA compliance training course, ... RAPS (Regulatory Affairs Professional Society) accredited interactive course on Morf Playbook—now conveniently available ...
(Date:2/4/2016)... (PRWEB) , ... February 04, 2016 , ... ... latest GC-MS and triple quad LC-MS, host live demos and poster sessions, and ... conference and exhibition. The conference takes place March 6 to 10 at the ...
(Date:2/4/2016)... 4, 2016  CytoSorbents Corporation (NASDAQ: CTSO ... flagship CytoSorb® blood filter to treat deadly inflammation ... world, announced that CEO Dr. Phillip Chan ... Capital Group,s 2016 Disruptive Growth & Healthcare Conference, ... Conference Presentation Details: Where: Convene ...
Breaking Biology Technology:
(Date:2/2/2016)... , Feb. 2, 2016   Parabon NanoLabs ... the U.S. Army Research Office and the Defense ... and sensitivity of the company,s Snapshot Kinship ... Mission and, more generally, defense-related DNA forensics.  Although ... capabilities (predicting appearance and ancestry from DNA evidence), ...
(Date:1/28/2016)... 28, 2016 Synaptics (NASDAQ: SYNA ), a leading ... second quarter ended December 31, 2015. --> ... fiscal 2016 increased 2 percent compared to the comparable quarter last ... fiscal 2016 was $35.0 million, or $0.93 per diluted share. ... for the first quarter of fiscal 2016 grew 9 percent over ...
(Date:1/22/2016)... Jan. 22, 2016 ... of the "Global Biometrics Market in ... offering. --> http://www.researchandmarkets.com/research/p74whf/global_biometrics ) ... "Global Biometrics Market in Retail Sector 2016-2020" ... --> Research and Markets ( http://www.researchandmarkets.com/research/p74whf/global_biometrics ...
Breaking Biology News(10 mins):